Since finalizing its risk-based monitoring guidance in 2013, the FDA is providing additional information in a new Q&A that reinforces the importance of performing risk assessments for all studies.
Since finalizing its risk-based monitoring guidance in 2013, the FDA is providing additional information in a new Q&A that reinforces the importance of performing risk assessments for all studies.
CluePoints is dedicated to revolutionizing clinical trials through AI, advanced statistics, and machine learning. Aligned with global regulatory guidance, our holistic risk-based approach is designed to drive positive outcomes. Ready to uncover the clues and pinpoint success in your next trial? Contact our expert team today.
